Which has preferable earnings & valuation, SOLV or BLCO?

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solventum $8.33B 1.83 $1.56B $8.18 10.96 Bausch + Lomb $5.10B 1.21 -$360M -$0.48 N/A

Is SOLV or BLCO more profitable?

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.26% 25.09% 8.78% Bausch + Lomb -3.21% 4.14% 1.93%

Bausch + Lomb (BLCO) Competitors

$17.25 +0.05 (+0.29%)

As of 08/21/2026 03:58 PM Eastern

Compare

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

Should you buy Bausch + Lomb stock or one of its competitors? Bausch + Lomb's main competitors and comparable companies include Solventum (SOLV), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), and ICU Medical (ICUI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Bausch + Lomb compare to Solventum?

Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Solventum currently has a consensus target price of $91.64, indicating a potential upside of 2.23%. Bausch + Lomb has a consensus target price of $18.75, indicating a potential upside of 8.70%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31

Solventum has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

In the previous week, Solventum had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for Solventum and 0 mentions for Bausch + Lomb. Solventum's average media sentiment score of 0.91 beat Bausch + Lomb's score of 0.00 indicating that Solventum is being referred to more favorably in the media.

Company	Overall Sentiment
Solventum	Positive
Bausch + Lomb	Neutral

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.33B	1.83	$1.56B	$8.18	10.96
Bausch + Lomb	$5.10B	1.21	-$360M	-$0.48	N/A

Solventum has a net margin of 17.26% compared to Bausch + Lomb's net margin of -3.21%. Solventum's return on equity of 25.09% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.26%	25.09%	8.78%
Bausch + Lomb	-3.21%	4.14%	1.93%

11.1% of Bausch + Lomb shares are owned by institutional investors. 0.2% of Solventum shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Solventum beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Cooper Companies?

Cooper Companies (NASDAQ:COO) and Bausch + Lomb (NYSE:BLCO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

24.4% of Cooper Companies shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 2.1% of Cooper Companies shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Cooper Companies has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Cooper Companies has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cooper Companies	$4.09B	3.63	$374.90M	$1.18	64.59
Bausch + Lomb	$5.10B	1.21	-$360M	-$0.48	N/A

In the previous week, Cooper Companies had 35 more articles in the media than Bausch + Lomb. MarketBeat recorded 35 mentions for Cooper Companies and 0 mentions for Bausch + Lomb. Cooper Companies' average media sentiment score of 0.97 beat Bausch + Lomb's score of 0.00 indicating that Cooper Companies is being referred to more favorably in the media.

Company	Overall Sentiment
Cooper Companies	Positive
Bausch + Lomb	Neutral

Cooper Companies has a net margin of 5.57% compared to Bausch + Lomb's net margin of -3.21%. Cooper Companies' return on equity of 10.88% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cooper Companies	5.57%	10.88%	7.27%
Bausch + Lomb	-3.21%	4.14%	1.93%

Cooper Companies currently has a consensus price target of $81.64, indicating a potential upside of 7.11%. Bausch + Lomb has a consensus price target of $18.75, indicating a potential upside of 8.70%. Given Bausch + Lomb's higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Cooper Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cooper Companies	3 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.35
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31

Summary

Cooper Companies beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Align Technology?

Bausch + Lomb (NYSE:BLCO) and Align Technology (NASDAQ:ALGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Align Technology has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.21	-$360M	-$0.48	N/A
Align Technology	$4.03B	2.89	$410.35M	$5.75	28.27

Bausch + Lomb currently has a consensus target price of $18.75, indicating a potential upside of 8.70%. Align Technology has a consensus target price of $206.36, indicating a potential upside of 26.95%. Given Align Technology's stronger consensus rating and higher possible upside, analysts plainly believe Align Technology is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67

Bausch + Lomb has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, Align Technology has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market.

In the previous week, Align Technology had 12 more articles in the media than Bausch + Lomb. MarketBeat recorded 12 mentions for Align Technology and 0 mentions for Bausch + Lomb. Align Technology's average media sentiment score of 1.18 beat Bausch + Lomb's score of 0.00 indicating that Align Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Neutral
Align Technology	Positive

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.4% of Align Technology shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 0.8% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Align Technology has a net margin of 9.99% compared to Bausch + Lomb's net margin of -3.21%. Align Technology's return on equity of 15.86% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Align Technology	9.99%	15.86%	10.32%

Summary

Align Technology beats Bausch + Lomb on 15 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Merit Medical Systems?

Bausch + Lomb (NYSE:BLCO) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Merit Medical Systems has a net margin of 9.22% compared to Bausch + Lomb's net margin of -3.21%. Merit Medical Systems' return on equity of 13.75% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
Merit Medical Systems	9.22%	13.75%	8.10%

Bausch + Lomb presently has a consensus price target of $18.75, indicating a potential upside of 8.70%. Merit Medical Systems has a consensus price target of $100.00, indicating a potential upside of 10.16%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31
Merit Medical Systems	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

Merit Medical Systems has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.21	-$360M	-$0.48	N/A
Merit Medical Systems	$1.58B	3.43	$128.49M	$2.42	37.51

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.7% of Merit Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Merit Medical Systems has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

In the previous week, Merit Medical Systems had 12 more articles in the media than Bausch + Lomb. MarketBeat recorded 12 mentions for Merit Medical Systems and 0 mentions for Bausch + Lomb. Merit Medical Systems' average media sentiment score of 1.03 beat Bausch + Lomb's score of 0.00 indicating that Merit Medical Systems is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Neutral
Merit Medical Systems	Positive

Summary

Merit Medical Systems beats Bausch + Lomb on 13 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to ICU Medical?

Bausch + Lomb (NYSE:BLCO) and ICU Medical (NASDAQ:ICUI) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

ICU Medical has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.21	-$360M	-$0.48	N/A
ICU Medical	$2.23B	2.05	$730K	$1.18	154.95

Bausch + Lomb presently has a consensus target price of $18.75, indicating a potential upside of 8.70%. ICU Medical has a consensus target price of $192.80, indicating a potential upside of 5.45%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than ICU Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	7 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.31
ICU Medical	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, ICU Medical had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for ICU Medical and 0 mentions for Bausch + Lomb. ICU Medical's average media sentiment score of 1.18 beat Bausch + Lomb's score of 0.00 indicating that ICU Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Bausch + Lomb	Neutral
ICU Medical	Positive

Bausch + Lomb has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, ICU Medical has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 96.1% of ICU Medical shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 2.1% of ICU Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ICU Medical has a net margin of 1.39% compared to Bausch + Lomb's net margin of -3.21%. ICU Medical's return on equity of 7.91% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
ICU Medical	1.39%	7.91%	4.17%

Summary

ICU Medical beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$6.16B	$6.02B	$7.37B	$24.30B
Dividend Yield	N/A	1.75%	2.53%	3.70%
P/E Ratio	-35.94	26.67	272.60	30.31
Price / Sales	1.21	45.39	618.96	19.91
Price / Cash	10.33	33.24	78.62	32.49
Price / Book	0.96	6.23	13.05	6.77
Net Income	-$360M	$150.07M	$3.47B	$1.07B
7 Day Performance	1.24%	0.69%	2.09%	-0.65%
1 Month Performance	7.95%	8.91%	6.64%	3.38%
1 Year Performance	15.58%	8.07%	25.02%	14.90%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.4646 of 5 stars	$17.25 +0.3%	$18.75 +8.7%	+15.6%	$6.16B	$5.10B	N/A	13,000	Analyst Upgrade
SOLV Solventum	2.7486 of 5 stars	$88.53 +2.4%	$91.64 +3.5%	+22.0%	$15.08B	$8.33B	10.82	20,000	Analyst Upgrade
COO Cooper Companies	2.8047 of 5 stars	$76.17 -0.6%	$81.64 +7.2%	+1.3%	$14.86B	$4.09B	64.55	15,000	News Coverage Positive News
ALGN Align Technology	4.5196 of 5 stars	$181.31 +2.9%	$206.36 +13.8%	+8.7%	$12.99B	$4.03B	31.53	20,290	Positive News
MMSI Merit Medical Systems	3.4444 of 5 stars	$90.76 +0.3%	$100.00 +10.2%	+1.5%	$5.42B	$1.52B	37.50	7,500	Positive News Analyst Upgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Summary

How does Bausch + Lomb compare to Align Technology?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Summary

How does Bausch + Lomb compare to ICU Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. SOLV, COO, ALGN, MMSI, and ICUI

How does Bausch + Lomb compare to Solventum?

Do analysts prefer SOLV or BLCO?

Which has more risk and volatility, SOLV or BLCO?

Does the media prefer SOLV or BLCO?

Which has preferable earnings & valuation, SOLV or BLCO?

Is SOLV or BLCO more profitable?

Do institutionals and insiders believe in SOLV or BLCO?

Summary

How does Bausch + Lomb compare to Cooper Companies?

Do institutionals & insiders have more ownership in COO or BLCO?

Which has more volatility & risk, COO or BLCO?

Which has better valuation and earnings, COO or BLCO?

Does the media favor COO or BLCO?

Is COO or BLCO more profitable?

Do analysts rate COO or BLCO?

Summary

How does Bausch + Lomb compare to Align Technology?

Which has preferable valuation and earnings, BLCO or ALGN?

Do analysts prefer BLCO or ALGN?

Which has more volatility & risk, BLCO or ALGN?

Does the media refer more to BLCO or ALGN?

Do insiders & institutionals have more ownership in BLCO or ALGN?

Is BLCO or ALGN more profitable?

Summary

How does Bausch + Lomb compare to Merit Medical Systems?

Is BLCO or MMSI more profitable?

Do analysts prefer BLCO or MMSI?

Which has stronger earnings & valuation, BLCO or MMSI?

Do insiders and institutionals have more ownership in BLCO or MMSI?

Which has more risk and volatility, BLCO or MMSI?

Does the media refer more to BLCO or MMSI?

Summary

How does Bausch + Lomb compare to ICU Medical?

Which has stronger valuation and earnings, BLCO or ICUI?

Do analysts recommend BLCO or ICUI?

Does the media favor BLCO or ICUI?

Which has more risk and volatility, BLCO or ICUI?

Do institutionals & insiders have more ownership in BLCO or ICUI?

Is BLCO or ICUI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools